116 related articles for article (PubMed ID: 3357653)
1. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period.
Haas S; Walsh B; Evans S; Krache M; Ravnikar V; Schiff I
Obstet Gynecol; 1988 May; 71(5):671-6. PubMed ID: 3357653
[TBL] [Abstract][Full Text] [Related]
2. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
3. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
4. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin dynamics in women receiving immediate or delayed transdermal estradiol after oophorectomy.
Kamel EM; Maurer SA; Hochler MG; Hoffman DI; Rebar RW
Obstet Gynecol; 1991 Jul; 78(1):98-102. PubMed ID: 1904568
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
8. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
10. The effect of acute ethanol ingestion on estrogen levels in postmenopausal women using transdermal estradiol.
Ginsburg ES; Walsh BW; Gao X; Gleason RE; Feltmate C; Barbieri RL
J Soc Gynecol Investig; 1995; 2(1):26-9. PubMed ID: 9420845
[TBL] [Abstract][Full Text] [Related]
11. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
12. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
13. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
[TBL] [Abstract][Full Text] [Related]
14. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
15. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
Mizunuma H
Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hot flashes with transdermal estradiol administration.
Steingold KA; Laufer L; Chetkowski RJ; DeFazio JD; Matt DW; Meldrum DR; Judd HL
J Clin Endocrinol Metab; 1985 Oct; 61(4):627-32. PubMed ID: 3928674
[TBL] [Abstract][Full Text] [Related]
18. [Transdermal estrogen treatment. A placebo controlled study].
Iversen OE; Eid AB; Johannesen KH; Nyland B; Løvset T
Tidsskr Nor Laegeforen; 1991 Aug; 111(20):2544-6. PubMed ID: 1948834
[TBL] [Abstract][Full Text] [Related]
19. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
